Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling

Published:2018-07-13 Issue:1 Volume:37 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Cai Mao-Hua,Xu Xiao-Gang,Yan Shi-Li,Sun Ze,Ying Yin,Wang Bai-Kui,Tu Yue-Xing

Funder

Funds of Science Technology Department of Zhejiang Province

Zhejiang Province Bureau of Health

Zhejiang Provincial Natural Science Foundation of China

the National Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-018-0836-x.pdf

Reference25 articles.

1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet (London, England). 2014;383:1490–502.

2. Lu CS, Shieh GS, Wang CT, Su BH, Su YC, Chen YC, Su WC, Wu P, Yang WH, Shiau AL, et al. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. Oncotarget. 2017;8:30844–58.

3. Bertocchi P, Aroldi F, Prochilo T, Meriggi F, Beretta GD, Zaniboni A. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope? Journal of chemotherapy (Florence, Italy). 2017;29:102–5.

4. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–55.

5. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2015;16:619–29.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Wnt/β-catenin pathway in cancer drug resistance: Insights into molecular aspects of major solid tumors;Biochemical and Biophysical Research Communications;2024-10

2. Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status;Oncotarget;2024-07-02

3. Targeted Treatment against Cancer Stem Cells in Colorectal Cancer;International Journal of Molecular Sciences;2024-06-05

4. Developing theragnostics for Alzheimer's disease: Insights from cancer treatment;International Journal of Biological Macromolecules;2024-06

5. MicroRNA-34 and gastrointestinal cancers: a player with big functions;Cancer Cell International;2024-05-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3